In clinical trials, systemic administration of an anti-C5 monoclonal antibody did not slow the rate of progression of AMD (146), whereas intravitreal administration of C3 inhibitor pegcetacoplan did (12). The gene discussed is C3; the disease is age-related macular degeneration.